Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Income from Continuing Operations (2022 - 2025)

TriSalus Life Sciences' Income from Continuing Operations history spans 4 years, with the latest figure at 9753000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 3.51% year-over-year to 9753000.0; the TTM value through Dec 2025 reached 39227000.0, down 30.56%, while the annual FY2025 figure was 39227000.0, 30.56% down from the prior year.
  • Income from Continuing Operations reached 9753000.0 in Q4 2025 per TLSIW's latest filing, up from 10811000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2836725.0 in Q1 2022 to a low of 35639000.0 in Q4 2023.
  • Average Income from Continuing Operations over 4 years is 9624377.25, with a median of 9020500.0 recorded in 2025.
  • The largest YoY upside for Income from Continuing Operations was 82.39% in 2023 against a maximum downside of 685.61% in 2023.
  • A 4-year view of Income from Continuing Operations shows it stood at 22542000.0 in 2022, then tumbled by 58.1% to 35639000.0 in 2023, then surged by 71.64% to 10108000.0 in 2024, then rose by 3.51% to 9753000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Income from Continuing Operations are 9753000.0 (Q4 2025), 10811000.0 (Q3 2025), and 8288000.0 (Q2 2025).